Prosecution Insights
Last updated: November 04, 2026
Application No. 17/440,447

COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME

Non-Final OA §102§103
Filed
Sep 17, 2021
Priority
Mar 18, 2019 — provisional 62/819,724 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Score Pharma Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
885 granted / 1249 resolved
+10.9% vs TC avg
Minimal +1% lift
Without
With
+1.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
94 currently pending
Career history
1321
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1249 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election without traverse of Group II (methods), and species of ECG, transtuzumab, CHO cell and HER2, in the replies filed on June 6, 2025 and July 23, 2026 is acknowledged. 3. Claim 19 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter. Election was made without traverse in the replies filed on June 6, 2025 and July 23, 2026. 4. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be novel and nonobvious over the prior art. Therefore, the search and examination was extended. Prior art was found that anticipates nonelected species. The Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and the nonelected species shown below. Information Disclosure Statement 5. The information disclosure statements (dated April 28, 2022 and January 19, 2023 and July 24, 2024) were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 1449 are enclosed herewith. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 6. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Niu et al. The reference has a date of 2004 which antedates the present claims having an effective filing date of March 16, 2020 and priority claim to application dated 2019. The reference teaches the inhibition of fucosyltransferase by gallic acid and derivatives such as ECGC. See abstract, page 53. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 7. Claim(s) 2-6, 13-18 and 20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Niu et al. in view of Beuger et al. (US 20110151513). Determining the scope and contents of the prior art Niu et al. teaches the inhibition of fucosyltransferase by gallic acid and derivatives, for example, ECGC. The reference suggests the inhibition of fucosyltransferase inside a cell and in vivo. For example page 51, page 55, column 2. Relevant to claim 2. “At a cellular level they have been shown to inhibit cell adhesion, induce apoptosis of tumor cells...” “This finding could help to further our understanding of many in vivo effects of these compounds...” Beuger et al. teaches the inhibition of fucosyltransferase in mammalian cells, including, CHO cells. For example, paragraph [0031]. Relevant to claim 20. The limitations recited in claims 3-6, 13-18 are inherent to the structure and activity of the inhibitor of fucosyltransferase. Ascertaining the differences between the prior art and the claims at issue The difference between Niu et al. and the present claims are the limitations of claims 2-6, 13-18 and 20 are not explicitly taught. Moreover, the difference is the application of the inhibition of fucosytransferase inhibition specifically to CHO cells. Resolving the level of ordinary skill in the pertinent art - considering objective evidence present in the application indicating obviousness The skilled artisan has the teaching and suggestion to practice the presently claimed methods. The motivation is to apply the explicit teaching to a pharmacological setting, such as in a cell or in vivo. The skilled artisan has a reasonable expectation of success in practicing the invention in the present claims. For these reasons, the claims are found to be prima facie obvious over the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 17, 2021
Application Filed
Jun 06, 2025
Response after Non-Final Action
Jan 08, 2026
Response Filed
Jul 16, 2026
Examiner Interview Summary
Jul 16, 2026
Examiner Interview (Telephonic)
Jul 23, 2026
Response Filed
Oct 02, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780779
CXCR6 SULFONAMIDE COMPOUNDS
3y 7m to grant Granted Nov 03, 2026
Patent 12780778
CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
3y 3m to grant Granted Nov 03, 2026
Patent 12780795
CRYSTALLINE FORM OF TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
2y 11m to grant Granted Nov 03, 2026
Patent 12778121
ACRYLATE DERIVATIVE, USE AND PRODUCTION INTERMEDIATE COMPOUND OF THE SAME
2y 3m to grant Granted Nov 03, 2026
Patent 12767631
METHOD FOR PRODUCING POLYETHER NITRILE
2y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
72%
With Interview (+1.0%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1249 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month